Tweaking the pirfenidone molecule yields an evidently effective but less toxic antifibrotic drug, investigators say.

Boehringer Ingelheim’s long-awaited phase 3 lung disease data received a muted reception from analysts who labeled ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

Lung cancer remains the leading cause of cancer ... To investigate the origins of LUSC, the team labeled Krt5-expressing basal cells in the trachea of two groups of mice so that the descendants ...

ZL-1310 earns fast track designation in extensive-stage small cell lung cancer after early trial data showed tumor shrinkage ...

The test processes whole-slide images of non-small cell lung cancer tissue to provide a quantitative TROP2 score, which Roche says provides a level of precision beyond manual methods. TROP2 has ...

Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin ...

Avalyn Pharma Inc., a clinical-stage biopharmaceutical company developing inhaled therapies for the treatment of ...

The US Food and Drug Administration (FDA) has approved treprostinil inhalation powder (YUTREPIA), a prostacyclin analog ...

Since being established in 1992 by the Environmental Protection Agency (EPA), the Energy Star program has delivered one of the greatest environmental, public health and consumer success stories in U.S ...

An ATS 2025 session presented data showing that anti–IL-5 biologics significantly cut exacerbations in coexisting asthma and ...

Only one fourth of sunscreens on store shelves in the United States deliver safe and effective protection against the harmful ...